Incyte presents JAK inhibitor data at ACR

US drug discovery firm Incyte presented results from a 28-day Phase IIa trial of its orally-available Janus kinase inhibitor INCB18424 in patients with rheumatoid arthritis at the American College of Rheumatology meeting in San Francisco.

Results from the 50-patient placebo-controlled trial demonstrated that three of the four doses of INCB18424 evaluated (15mg, 25mg and 50mg) produced impressive clinical benefits and all of these were well tolerated. ACR 20, ACR 50, ACR 70 and ACR 90 response rates in the three most effective dose groups ranged from 50% to 83%, 40% to 50%, 25% to 30%, 10% to 17%, respectively, and were achieved in one month, with responses seen as early as one week.